STOCK TITAN

NanoVibronix (NAOV) Financials

NAOV NASDAQ

Ticker history: NAOV became FEED (ENvue Medical Inc New) on .

Trailing 12 months to March 31, 2026
Revenue $2.2M -18.1% YoY
Net Income -$20.1M n/m YoY
EPS (Diluted) -$26.69 FY2025 annual
Free Cash Flow -$12.4M n/m YoY
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 18, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NAOV SEC filings page.

NanoVibronix, Inc. (NAOV) reported $2.2M in revenue over the twelve months to Mar 31, 2026, down 18.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NAOV FY2025

FY2025 shows flat sales but collapsing gross economics, with the balance sheet enlarged mainly by goodwill rather than operating scale.

Revenue fell 0.2% while cost of revenue rose 128.6% from FY2024 to FY2025. That combination drove gross margin down 53.0 percentage points to 6.0%, making near-flat sales economically far less productive.

Total assets expanded 1033.2% while revenue fell 0.2%, separating balance-sheet growth from operating growth. Goodwill was $29.1M, indicating that most of the asset expansion was not generated by greater sales volume.

The company reported a net loss of $18.2M versus operating cash flow of -$9.4M, indicating a meaningful noncash component in reported losses. Free cash flow was -$9.4M against only $60K of capital spending, so cash use was overwhelmingly operational rather than reinvestment-led.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 32 / 100
Financial Health Score (5 of 6 dimensions) 32/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of NanoVibronix, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
21

NanoVibronix, Inc. held $4.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $9.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and NanoVibronix, Inc. scores 21/100 among other emerging companies.

Dilution
n/a

Not available for NanoVibronix, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

R&D Intensity
31

NanoVibronix, Inc. spent $1.8M on research and development in fiscal year 2025, which was 6.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and NanoVibronix, Inc. scores 31/100 among other emerging companies.

Revenue Progress
48

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. NanoVibronix, Inc. scores 48/100 on it among other emerging companies.

Burn Trend
15

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. NanoVibronix, Inc. scores 15/100 on it among other emerging companies.

Balance Sheet
46

NanoVibronix, Inc.'s cash, cash equivalents and investments came to $4.2M at the end of fiscal year 2025, against $7.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and NanoVibronix, Inc. scores 46/100 among other emerging companies.

Piotroski F-Score Partial
2/8

NanoVibronix, Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing
N/A

NanoVibronix, Inc. reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$653K
YoY-36.3%
QoQ+109.3%

NanoVibronix, Inc. generated $653K in revenue in Q1 2026. This represents a decrease of 36.3% from the same quarter a year earlier. Against the prior quarter it is up 109.3%.

EBITDA
-$3.5M
YoYn/m

NanoVibronix, Inc.'s EBITDA was -$3.5M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Net Income
-$3.8M
YoYn/m
QoQn/m

NanoVibronix, Inc. reported a net loss of $3.8M in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$6.88

NanoVibronix, Inc. earned -$6.88 per diluted share (EPS) in Q1 2026.

Cash & Balance Sheet

Free Cash Flow
-$4.3M
YoYn/m
QoQn/m

NanoVibronix, Inc. recorded an outflow of $4.3M in free cash flow in Q1 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$2.2M
YoY+291.4%
QoQ-47.1%
5Y CAGR-22.4%

NanoVibronix, Inc. held $2.2M in cash as of Q1 2026; no long-term debt figure is on record for that period.

Shares Outstanding
4M

NanoVibronix, Inc. had 4M shares outstanding in Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Gross Margin
-8.4%
YoY-44.4pp

NanoVibronix, Inc.'s gross margin was -8.4% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is down 44.4 percentage points from the same quarter a year earlier.

Return on Equity
-11.9%
YoY-6.7pp
QoQ+26.4pp

NanoVibronix, Inc.'s quarterly ROE was -11.9% in Q1 2026: one quarter's net income over shareholder equity, not annualized. This is down 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 26.4 percentage points.

Operating Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$468K
YoY-11.7%
QoQ+1100.0%

NanoVibronix, Inc. invested $468K in research and development in Q1 2026. This represents a decrease of 11.7% from the same quarter a year earlier. Against the prior quarter it is up 1100.0%.

Capital Expenditures
$17K
YoY+240.0%
QoQ-26.1%

NanoVibronix, Inc. invested $17K in capex in Q1 2026, funding long-term assets and infrastructure. This represents an increase of 240.0% from the same quarter a year earlier. Against the prior quarter it is down 26.1%.

Share Buybacks

Not reported for Q1 2026.

NAOV Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NAOV quarterly income statement
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Revenue$653K-36.3%$312K-29.7%$722K+92.0%$494K-39.5%$1.0M+11.3%$444K-62.3%$376K-17.9%$817K+177.9%
Cost of Revenue$708K+7.9%$682K+323.6%$533K+119.3%$529K+36.0%$656K+155.3%$161K-63.4%$243K+122.9%$389K+398.7%
Gross Profit-$55K-114.9%-$370K-230.7%$189K+42.1%-$35K-108.2%$369K-44.4%$283K-61.6%$133K-61.9%$428K+98.1%
R&D Expenses$468K-11.7%$39K-88.9%$221K-11.2%$972K+419.8%$530K+338.0%$352K+467.7%$249K+654.5%$187K+434.3%
SG&A Expenses$2.4M+80.0%$2.6M+134.1%$1.4M+108.5%$2.3M+214.5%$1.3M+41.9%$1.1M-1.6%$673K-15.5%$716K-25.6%
Operating Income-$3.7Mn/m-$14.8Mn/m-$2.2Mn/m-$4.0Mn/m-$1.9Mn/m-$1.4Mn/m-$970Kn/m-$674Kn/m
EBITDA-$3.5Mn/mN/AN/AN/A-$1.8MN/AN/AN/A
Interest Expense$36K-32.1%N/A$53K+60.6%$144K+323.5%$53K+55.9%$34K+3.0%$33K-5.7%$34K+3.0%
Income Tax$33K+120.0%-$419K-8480.0%$35K+1066.7%$62K+1450.0%$15K+114.3%$5K-54.5%$3K0.0%$4K-69.2%
Net Income-$3.8Mn/m-$12.9Mn/m$510Kn/m-$4.0Mn/m-$1.9Mn/m-$1.4Mn/m-$998Kn/m-$688Kn/m
EPS (Basic)-$6.88N/A-$0.91-$1.03-$29.90N/A-$3.56-$27.18
EPS (Diluted)-$6.88N/A-$0.91-$1.03-$29.90N/A-$3.56-$27.18
Diluted Shares (Avg)3MN/A858,434484,56662,615N/A280,31825,312

NAOV Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NAOV quarterly balance sheet
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Total Assets$39.9M-9.6%$41.1M+1033.2%$54.4M+1061.5%$51.5M+803.8%$44.1M+607.4%$3.6M-45.6%$4.7M-36.4%$5.7M+48.7%
Current Assets$6.2M+60.6%$7.3M+118.3%$10.0M+128.8%$6.9M+28.0%$3.9M-35.1%$3.3M-48.7%$4.4M-38.9%$5.4M+49.0%
Cash & Equivalents$2.2M+291.4%$4.2M+461.7%$7.0M+432.6%$4.0M+85.7%$571K-78.9%$752K-77.1%$1.3M-65.5%$2.2M+757.7%
Inventory$2.3M+12.2%$2.3M+6.7%$2.2M-0.3%$2.2M-9.3%$2.0M-22.0%$2.2M-19.8%$2.3M-29.2%$2.4M-21.9%
Accounts Receivable$332K-7.3%$289K+194.9%$252K-56.6%$115K-76.5%$358K-0.6%$98K-69.2%$580K+1712.5%$489K+588.7%
Goodwill$29.1M-14.2%$29.1M$38.6M$38.6M$33.9MN/AN/AN/A
Total Liabilities$7.9M-6.8%$7.6M+154.1%$11.9M+324.2%$11.0M+285.5%$8.4M+208.7%$3.0M+11.8%$2.8M+5.2%$2.9M+7.1%
Current Liabilities$6.9M-16.3%$6.7M+144.7%$11.6M+361.9%$6.5M+156.0%$8.2M+237.9%$2.7M+10.9%$2.5M+5.4%$2.6M+7.8%
Non-Current Liabilities$991K+330.9%$967K+245.4%$275K-4.8%$4.5M+1392.3%$230K-24.3%$280K+20.7%$289K+3.6%$299K+1.0%
Long-Term DebtN/AN/AN/AN/A$1.3MN/AN/AN/A
Total Equity$32.0M-10.3%$33.5M+5242.4%$42.5M+2168.4%$40.5M+1324.7%$35.7M+918.1%$627K-84.3%$1.9M-60.1%$2.8M+143.9%
Retained Earnings-$112.1Mn/m-$90.5Mn/m-$76.9Mn/m-$76.0Mn/m-$72.3Mn/m-$69.8Mn/m-$68.4Mn/m-$67.4Mn/m

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.

NAOV Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NAOV quarterly cash flow statement
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Operating Cash Flow-$4.3Mn/m-$2.7Mn/m-$2.0Mn/m-$3.4Mn/m-$1.3Mn/m-$548Kn/m-$836Kn/m-$553Kn/m
Depreciation & Amortization$217K+1105.6%N/AN/AN/A$18KN/AN/AN/A
Capital Expenditures$17K+240.0%$23Kn/m$28Kn/m$4K+100.0%$5K+400.0%$0n/m$0n/m$2Kn/m
Free Cash Flow-$4.3Mn/m-$2.7Mn/m-$2.0Mn/m-$3.4Mn/m-$1.3Mn/m-$548Kn/m-$836Kn/m-$555Kn/m
Investing Cash Flow-$17K-111.9%-$23Kn/m-$28Kn/m-$4Kn/m$143Kn/m$0n/m$0n/m-$2Kn/m
Financing Cash Flow$2.3M+122.9%-$34Kn/m$4.9Mn/m$6.8M$1.1M$0n/m-$27K-100.6%N/A

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

NAOV Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

NAOV quarterly financial ratios
MetricQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-Q
Gross Margin-8.4%-44.4pp-118.6%26.2%-9.2pp-7.1%-59.5pp36.0%-36.1pp63.7%+1.1pp35.4%-40.8pp52.4%-21.1pp
Operating Margin-568.3%-4748.1%-311.2%-804.9%-180.7%-308.6%-258.0%-82.5%
Net Margin-585.3%-4119.2%70.6%-803.9%-182.6%-322.3%-265.4%-84.2%
Return on Equity-11.9%-6.7pp-38.4%+189.9pp1.2%+54.5pp-9.8%+14.4pp-5.3%+11.5pp-228.2%-207.8pp-53.3%-37.8pp-24.2%+68.0pp
Return on Assets-9.6%-5.3pp-31.3%+8.2pp0.9%+22.3pp-7.7%+4.4pp-4.2%+5.2pp-39.4%-27.2pp-21.3%-11.4pp-12.1%+15.9pp
Current Ratio0.90+0.4x1.09-0.1x0.86-0.9x1.05-1.1x0.47-2.0x1.22-1.4x1.74-1.3x2.11+0.6x
Debt-to-EquityN/AN/AN/AN/A0.04N/AN/AN/A
Liabilities-to-Equity0.250.0x0.23-4.6x0.28-1.2x0.27-0.7x0.24-0.5x4.79+4.1x1.50+0.9x1.00-1.3x
Asset Turnover0.020.0x0.01-0.1x0.01-0.1x0.01-0.1x0.02-0.1x0.12-0.1x0.080.0x0.14+0.1x
FCF Margin-662.9%-865.1%-276.7%-685.6%-131.5%-123.4%-222.3%-67.9%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
NanoVibronix, Inc. NAOV FY2025 $2.6M -$18.2M N/A N/A 32/100
SANUWAVE Health, Inc. SNWV FY2025 $44.1M $11.8M 26.8% $12.9M 61/100
Medtronic plc MDT FY2026 $36.4B $4.8B 13.2% $127.8B 63/100
Integer Holdings Corporation ITGR FY2025 $1.9B $102.8M 5.5% $4.3B 59/100
Apyx Medical Corporation APYX FY2025 $52.8M -$11.2M -21.2% $101.1M 46/100
TELA Bio, Inc. TELA FY2025 $80.3M -$38.8M -48.4% $31.1M 48/100

Frequently Asked Questions

NanoVibronix, Inc. (NAOV) reported $2.6M in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

NanoVibronix, Inc. (NAOV) revenue declined by 0.2% year-over-year, from $2.6M to $2.6M in fiscal year 2025.

No, NanoVibronix, Inc. (NAOV) reported a net loss of $20.1M over the trailing 12 months to March 31, 2026. In fiscal year 2025 it reported a net loss of $18.2M.

NanoVibronix, Inc. (NAOV) reported diluted earnings per share of -$26.69 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NanoVibronix, Inc. (NAOV) had EBITDA of -$22.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

NanoVibronix, Inc. (NAOV) had a gross margin of 6.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

NanoVibronix, Inc. (NAOV) has a return on equity of -54.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

NanoVibronix, Inc. (NAOV) recorded an outflow of $9.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

NanoVibronix, Inc. (NAOV) recorded an outflow of $9.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

NanoVibronix, Inc. (NAOV) had $41.1M in total assets as of fiscal year 2025, including both current and long-term assets.

NanoVibronix, Inc. (NAOV) invested $60K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

NanoVibronix, Inc. (NAOV) invested $1.8M in research and development during fiscal year 2025.

NanoVibronix, Inc. (NAOV) had 1M shares outstanding as of fiscal year 2025.

NanoVibronix, Inc. (NAOV) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.

NanoVibronix, Inc. (NAOV) had a liabilities-to-equity ratio of 0.23 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

NanoVibronix, Inc. (NAOV) had a return on assets of -44.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

At the end of fiscal year 2025, NanoVibronix, Inc. (NAOV) held $4.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $9.4M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

NanoVibronix, Inc. (NAOV) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

NanoVibronix, Inc. (NAOV) reported a net loss of $18.2M while operations used $9.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

NanoVibronix, Inc. (NAOV) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For NanoVibronix, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top